A review of six placebo-controlled scientific trials with one,134 whole contributors concluded that cannabinoids (nabiximols, dronabinol, and THC/CBD) ended up connected with a larger regular enhancement within the Ashworth scale for spasticity in various sclerosis patients compared with placebo